myScience

You have already an academic degree or you are working since many years? You want to learn new qualifications in a particular discipline or in your domain of activities. You will find in the continuing education portal offers on academic level organised by universities and universities of applied sciences.


Advanced Therapy Medicinal Products

	Formation Continue Unil-EPFL Faculty of Biology and Medicine (FBM), University of Lausanne (UNIL), Switzerland Faculty of Science, University of Geneva (UNIGE), Switzerland Steering committee Co-presidents Prof. Chantal Csajka, Full professor, Director of the Centre for Research and
Location	Lausanne, Lake Geneva region, Switzerland
Category	Health Pharmacology
type	CAS
Deadline	31 May 2023
Target audience Healthcare professionals and scientists interested in the emerging field of advanced therapies, including pharmacists, physicians, medical researchers, biologists, healthcare engineers, biostatisticians Introduction Advanced therapy medicinal products (ATMPs) such as cell therapy, tissue-engineered medicine or immunotherapy, as well as innovative medicines like phage therapy or nanomedicine, are pushing the boundaries of currently available treatments. Oncology, reconstructive surgery, orthopaedic surgery, neurosurgery, blood transfusion, infectious diseases - clinical applications are numerous. Providing healthcare professionals with a thorough understanding of these therapeutic breakthroughs is essential to ensure the effective transition of these innovative treatments and care techniques from the bench to the bedside. Discover therapeutic advances in standardized transplants, cell-based products, blood products, complex and personalized medicines and innovative drug combinations Cursus & Certification The Certificate of Advanced Studies (CAS) in Advanced Therapy Medicinal Products is combining face-to-face and synchronous online teaching. It totals 392 hours of training, divided into 7 modules. Face-to-face teaching (38h) Plenary sessions, panel discussions, practical laboratory activities, visits of labs and manufacturing facilities Title obtained: Certificate of Advanced Studies (CAS) in Advanced Therapy Medicinal Products delivered by the universities of Lausanne and Geneva, 16 ECTS credits. Program Module 1 Cellular therapy - from bench to bedside 7h face-to-face teaching + 14h online teaching + ~ 45h individual work Thur November 16, 2023 / Fri November 17, 2023 / Fri February 9, 2024 Principles of translational science Cell biology / Preclinical relevance and evaluation / Biological products specificities Types of cellular therapy Sources of cells / Clinical targets / Clinical strategies / Histocompatibility Clinical trials of cellular therapy Examples of human applications: burn patients, orthopedics, neuroscience Regulatory aspects of cellular therapy Basis in EU and Switzerland for Good Manufacturing Practices (GMP), Good Clinical Practices (GCP) & ATMPs specificities Module leaders: Prof. Lana Kandalaft and Dr Jean-François Brunet -------------– Module 2 Immunology 7h online teaching + ~15h individual work Fri December 15, 2023 Introduction to immunology Organs, tissues, functions of the immune system / Innate & adaptive immunity Module leader: Prof. Alexandre Harari -------------– Module 3 Transfusion medicine - science and technology from donor to patient 7h face-to-face teaching + 14h online teaching + ~ 45h individual work Thur Januray 11, 2024 / Fri January 12, 2024 / Thur February 8, 2024 Introduction to transfusion medicine Historical developments / Transfusion chain / Blood groups / Immunohematology / Transfusion-related risks Biology and biochemistry of blood products Red blood cells and platelets / Fresh frozen Plasma Medical aspects Needs and use of blood products / Apheresis / Hematopoietic stem cells / Clinical cases and practices Production and regulatory aspects Blood & special products preparation and manufacturing / Regulations and GMP Module leader: Prof. Michel Prudent -------------– Module 4 Combinatorial strategies in cancer treatment 7h face-to-face teaching + 21h online teaching + ~ 60h individual work Thur March 14, 2024 / Fri March 15, 2024 / Fri March 22, 2024 / Wed June 12, 2024 Combination therapy Advantages vs. monotherapy / Combinations strategies in various cancer types / Anti-angiogenic immunotherapy / Pharmacokinetics and pharmacodynamics / Drug resistance principles / Cell death in cancer therapy Preclinical development Drug repurposing / Drug interactions and synergies / Immunotargeting / Cell mitosis Clinical development Clinical trial development / Successful clinical trials examples / New combination strategies for cancer treatment design Module leader: Prof. Patrycja Nowak-Sliwinska -------------– Module 5 Oncology: innovative therapies 7h face-to-face teaching + 14h online teaching + ~ 45h individual work Thur April 11, 2024 / Fri April 12, 2024 / Fri June 14, 2024 Immunotherapy Cellular and drug immunotherapies / Checkpoint inhibitors / Monoclonal antibodies Personalized cellular immunotherapy Chimeric Antigen Receptor (CAR) T cell / Vaccines / HSCT / Personalized medicine Module leader: Dr Francesco Ceppi -------------– Module 6 Phage therapy 10h face-to-face teaching + 7h online teaching + ~ 45h individual work Fri April 19, 2024 / Wed June 12, 2024 / Thur June 13, 2024 Introduction to phage therapy Antibiotic resistance / Bacteriophages / History of phage discovery & phage therapy Modern translational studies and clinical studies Phage-antibiotic synergism / Human applications Module leader: Dr Grégory Resch -------------– Module 7 Nanomedicines 7h online teaching + ~ 15h individual work Fri May 17, 2024 Introduction to nanomedicines Nanomedicines types / Nanotechnology applications to drug therapies and vaccines / Pharmacokinetics & pharmacodynamics Nanomedicines technology Physiochemical properties biocompatibility / Nanoformulations / Critical Quality Attributes (CQAs) Production and regulatory aspects FDA and EMA regulations / The many challenges of nanomedicines development, production and clinical practices Steering committee Co-presidents Prof. Chantal Csajka, Full professor, Director of the Centre for Research and Innovation in Clinical Pharmaceutical Sciences, Lausanne University Hospital and UNIL; School of Pharmaceutical Sciences, UNIGE Prof. Lana Kandalaft, Chief of Service – Center of Experimental Therapeutics, Lausanne University Hospital and UNIL ; Associate Director for Clinical Translation - Ludwig Institute for Cancer Research Prof. Patrycja Nowak-Sliwinska, Associate Professor, Head of the Molecular Pharmacology Group, School of Pharmaceutical Sciences, UNIGE Prof. Michel Prudent, Associate Professor, Head of Innovation and Therapeutic Products, Transfusion Interrégionale CRS SA; Centre for Research and Innovation in Clinical Pharmaceutical Sciences, Lausanne University Hospital and UNIL Dr Grégory Resch, Senior Lecturer, Head of the Bacteriophage and Phage Therapy Laboratory, Centre for Research and Innovation in Clinical Pharmaceutical Sciences, Lausanne University Hospital and UNIL Dr Grégory Resch, Senior Lecturer, Head of the Bacteriophage and Phage Therapy Laboratory, Centre for Research and Innovation in Clinical Pharmaceutical Sciences, Lausanne University Hospital and UNIL Dr Jean-François Brunet, Head of the Cell Manufacturing Center, Service of Pharmacy, Lausanne University Hospital and UNIL Prof. Lana Kandalaft, Chief of Service – Center of Experimental Therapeutics, Lausanne University Hospital and UNIL ; Associate Director for Clinical Translation - Ludwig Institute for Cancer Research Prof. Alexandre Harari, Associate Professor, Head of the Tumor Immunology laboratory, Department of Oncology, Lausanne University Hospital and UNIL Dr Francesco Ceppi, Lecturer and Medical Oncologist, Unit of Pediatric Oncology Hematology, Lausanne University Hospital and UNIL Prof. Patrycja Nowak-Sliwinska, Associate Professor, Head of the Molecular Pharmacology Group, School of Pharmaceutical Sciences, UNIGE Prof. Michel Prudent, Associate Professor, Head of Innovation and Therapeutic Products, Transfusion Interrégionale CRS SA; Centre for Research and Innovation in Clinical Pharmaceutical Sciences, Lausanne University Hospital and UNIL Prof. Gerrit Borchard, Full Professor, Head of the Biopharmaceutics laboratory, School of Pharmaceutical Sciences, UNIGE Practical information Course venue Online and onsite: Hold a bachelor’s or master’s degree from a Swiss or foreign university (HEU), from a University of Applied Sciences (HES), or hold another title deemed equivalent by the Steering Committee, and Registration Admission on file to submit to Formation Continue UNIL-EPFL. Please join to the registration form: To register, click here Course fee 6 000.- Swiss francs * * Payment in instalments possible Registration deadline May 31, 2023 Number of participants is limited Contact For academic questions: Dr. Michele Graciotti, Programme coordinator; Project Manager, Center of Experimental Therapeutics, Department of Oncology, Lausanne University Hospital and UNIL CAS.ATMP [a] unil[.]ch
More information
In your contacts, please refer to myScience.ch and reference edu.myScience.ch/id1606